Kerrie Brady, OcuTerra CEO

Low-pro­file eye drop de­vel­op­er spells out the game plan that drew Brent Saun­ders to the board — and it in­volves go­ing ear­li­er than an­ti-VEG­Fs

When Brent Saun­ders took on the chair­man role on OcuTer­ra Ther­a­peu­tics’ board of di­rec­tors a few months ago — his first biotech gig since sell­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.